Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 23:28:1610747.
doi: 10.3389/pore.2022.1610747. eCollection 2022.

Pulmonary Combined Large Cell Neuroendocrine Carcinoma

Meihui Li  1   2   3   4 , Lan Yang  1   2   3 , Hongyang Lu  1   2   3
Affiliations
Review

Pulmonary Combined Large Cell Neuroendocrine Carcinoma

Meihui Li et al. Pathol Oncol Res. .

Abstract

Pulmonary combined large-cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine tumor pertained to lung large cell neuroendocrine carcinoma (LCNEC) with aggressive behavior and poor prognosis generally. The clinical features of CLCNEC are not specific including cough, expectoration, chest distress, chest pain, etc., which are prone to have different manifestations of the mixed components. Owing to the low incidence, there are few related small-scale retrospective studies and case reports. Currently, the treatment regimen of CLCNEC mainly refers to LCNEC that complete surgical resection is preferred in the early stage and according to previous researches, platinum-based small cell lung cancer (SCLC) standard treatment regimen showed promising results in postoperative and advanced CLCNEC as compared to that of non-small cell lung cancer (NSCLC). Adenocarcinoma-CLCNEC more likely harbor driver gene mutation, and may benefit from targeted therapy. As for immunotherapy, more clinical trial data are needed to support its benefits. This article will fill the gap and will provide new insight into the clinical characteristics, pathological diagnosis and treatment endeavors of CLCNEC.

Keywords: diagnosis; pathological characteristics; pulmonary combined large cell neuroendocrine carcinoma (CLCNEC); targeted therapy; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Tanimoto H, Hamasaki A, Akimoto Y, Honda H, Takao Y, Okamoto K, et al. A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery. Gan To Kagaku Ryoho (2012) 39(9):1439–41. - PubMed
    1. Lee KW, Lee Y, Oh SW, Jin KN, Goo JM. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings. Eur J Radiol (2015) 84(11):2332–8. 10.1016/j.ejrad.2015.07.033 - DOI - PubMed
    1. Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: Current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol (2017) 12(3):425–36. 10.1016/j.jtho.2016.11.2222 - DOI - PubMed
    1. Coleman N, Wotherspoon A, Yousaf N, Popat S. Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer (2019) 134(8):117–20. 10.1016/j.lungcan.2019.05.025 - DOI - PubMed
    1. Fasano M, Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol (2015) 10(8):1133–41. 10.1097/jto.0000000000000589 - DOI - PMC - PubMed

MeSH terms